Results 131 to 140 of about 774,099 (307)

Characterization of an Injectable Poly(vinyl alcohol)‐gelatin Hydrogel for Growth Factor Delivery in an Orthopedic Application

open access: yesAdvanced Healthcare Materials, EarlyView.
This work introduces photo‐crosslinkable tyraminated poly(vinyl alcohol)‐gelatin (PVA‐GT) hydrogels as tunable injectable platforms for tissue engineering and growth factor delivery applications. This schematic illustrates the two developed hydrogel formulations and the experimental workflow used to evaluate their physico‐chemical properties in vitro ...
Alessia Longoni   +15 more
wiley   +1 more source

Cancer screening in end-stage renal disease

open access: yesSaudi Journal of Kidney Diseases and Transplantation, 2009
The increased risk of cancer after renal transplantation is well documented; however there is less agreement about the prevalence and risk of cancer in patients on dialysis. Although, certain cancers such as those of the kidney and urinary tract are more
Rao Shobhana
doaj  

Carotid intima-media thickness and left ventricular hypertrophy in hemodialysis patients. [PDF]

open access: yes, 2013
INTRODUCTION Two principal findings of cardiovascular disease in end-stage renal disease patients undergoing regular hemodialysis are left ventricular hypertrophy (LVH) and arterial disease due to rapidly progressive atherosclerotic vascular disease ...
Nasri, H., Rafieian-Kopaei, M.
core   +1 more source

Dual‐Peptide Nanoplatform: Mesoporous Silica Nanoparticles Functionalized With a Cell‐Penetrating Peptide and Loaded With Rationally Designed Antimicrobial Peptides for Tuberculosis Therapy

open access: yesAdvanced Healthcare Materials, EarlyView.
Machine learning–guided engineering of a plectasin‐derived peptide yields DC05, a potent antimycobacterial candidate. Encapsulation into tuftsin‐functionalized mesoporous silica nanoparticles enhances intracellular delivery, stability, and activity against Mycobacterium tuberculosis while maintaining low cytotoxicity and minimal hemolysis. The combined
Christian S. Carnero Canales   +12 more
wiley   +1 more source

Re: Risk of End-Stage Renal Disease Following Live Kidney Donation

open access: yesJournal of Urological Surgery, 2014
The authors compare the risk of end-stage renal disease (ESRD) in 96217 kidney donors in the United States, followed for a median of 7.6 years with that of a healthy cohort of 20024 nondonors, followed for a median of 15 years of who are at equally low ...
Muzaale AD   +6 more
doaj  

Serum uric acid and diabetic nephropathy. [PDF]

open access: yes, 2012
Implication for health policy/practice/research/medical education: Diabetic nephropathy is the most common cause of end-stage renal disease worldwide.
Momeni, A.
core   +2 more sources

INFLAMMATORY MARKERS IN END-STAGE RENAL DISEASE PATIENTS ON HAEMODIALYSIS

open access: diamond, 2020
Phebe L. Abdel-Messeih   +3 more
openalex   +2 more sources

Nanobody‐Conjugated Theranostic Prodrug Targeting αvβ3 Integrin Enables Precision Cancer Therapy With Real‐Time Imaging

open access: yesAdvanced Healthcare Materials, EarlyView.
The image shows a schematic form a nanobody‐conjugated theranostic prodrug (NBD) platform targeting tumor‐associated αvβ3 integrin. The NBD system integrates selective nanobody‐mediated tumor recognition, glutathione‐responsive disulfide cleavage for doxorubicin release, and aza‐BODIPY‐based near‐infrared fluorescence for real‐time imaging.
Sanu Karan   +13 more
wiley   +1 more source

Cost-effectiveness analysis of treatment for end-stage renal disease [PDF]

open access: yes, 2010
Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn Skoða/Opna(view/open)OBJECTIVE: End-stage renal disease (ESRD) requires costly life-sustaining therapy, either dialysis or kidney transplantation.
Eiríkur Jónsson   +4 more
core  

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

open access: yesAdvanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy